Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery
- PMID: 27630935
- PMCID: PMC5020194
- DOI: 10.7860/JCDR/2016/18181.8126
Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery
Abstract
Introduction: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear.
Aim: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.
Materials and methods: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.
Results: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.
Conclusion: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
Keywords: Chemotherapy; Radiation therapy; Radiosensitizing.
Figures
Similar articles
-
A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.J Clin Oncol. 1989 Jan;7(1):100-7. doi: 10.1200/JCO.1989.7.1.100. J Clin Oncol. 1989. PMID: 2909663
-
Concurrent chemoradiation in locally advanced head and neck cancers: a comparative study of weekly Paclitaxel versus Cisplatin-based regimen.J Egypt Natl Canc Inst. 2010 Sep;22(3):165-73. J Egypt Natl Canc Inst. 2010. PMID: 21863067
-
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.Jpn J Clin Oncol. 1998 Mar;28(3):168-75. doi: 10.1093/jjco/28.3.168. Jpn J Clin Oncol. 1998. PMID: 9614438 Clinical Trial.
-
Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.Hematol Oncol Clin North Am. 2004 Feb;18(1):41-53. doi: 10.1016/s0889-8588(03)00138-2. Hematol Oncol Clin North Am. 2004. PMID: 15005280 Review.
-
Different infusion durations for preventing platinum-induced hearing loss in children with cancer.Cochrane Database Syst Rev. 2016 Aug 8;(8):CD010885. doi: 10.1002/14651858.CD010885.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2018 Jul 05;7:CD010885. doi: 10.1002/14651858.CD010885.pub4 PMID: 27498707 Updated. Review.
Cited by
-
Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips.Nat Biomed Eng. 2020 Apr;4(4):421-436. doi: 10.1038/s41551-019-0498-9. Epub 2020 Jan 27. Nat Biomed Eng. 2020. PMID: 31988459 Free PMC article.
-
The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability.Physiol Rep. 2021 Jul;9(13):e14927. doi: 10.14814/phy2.14927. Physiol Rep. 2021. PMID: 34197700 Free PMC article.
-
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies.Cells. 2023 Apr 13;12(8):1145. doi: 10.3390/cells12081145. Cells. 2023. PMID: 37190054 Free PMC article.
-
Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines.Front Oncol. 2021 Dec 13;11:750677. doi: 10.3389/fonc.2021.750677. eCollection 2021. Front Oncol. 2021. PMID: 34966671 Free PMC article.
-
Unexpected Enhancement of Cytotoxicity of Cisplatin in a Rat Kidney Proximal Tubular Cell Line Overexpressing Mitochondrial Glutathione Transport Activity.Int J Mol Sci. 2022 Feb 11;23(4):1993. doi: 10.3390/ijms23041993. Int J Mol Sci. 2022. PMID: 35216119 Free PMC article.
References
-
- Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–98. - PubMed
-
- Chu E. Physicians’ Cancer Chemotherapy Drug Manual 2015. Jones & Bartlett Publishers; 2014. Chu P of MCD of H-ODDU of PCIPPE, Jr VTD, MD VTD Jr; p. 682.
-
- Marcu L, van Doorn T, Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer–a review of their cooperation. Acta Oncol Stockh Swed. 2003;42(4):315–25. - PubMed
-
- J:!GUIDANCFINALE6REV.PDF - ucm073122.pdf [Internet]. [cited 2016 Feb 26]. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073122.pdf.
LinkOut - more resources
Full Text Sources
Other Literature Sources